Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review [0.03%]
健康创新支付和定价方案的映射：协议性文献综述方案
Vittoria Ardito,Ludovico Cavallaro,Michael Drummond et al.
Vittoria Ardito et al.
Introduction: Innovative pricing and payment/reimbursement schemes have been proposed as one part of the solution to the problem of patient access to new health technologies or to the uncertainty about their long-term eff...
Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country [0.03%]
中等收入国家的健康危机下的公共卫生疫苗融资偏好——以COVID-19疫苗为例
Najmeh Moradi,Leila Zarei,Narges Hajimoladarvish et al.
Najmeh Moradi et al.
Background: To effectively manage health crises such as disease pandemics, health authorities require reliable information regarding people's preferences. This helps to ensure timely and targeted interventions and avoids ...
Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension [0.03%]
纠正：难治性高血压患者经血管超声肾去神经支配的 cost-effectiveness
Rod S Taylor,Anthony Bentley,Kaylie Metcalfe et al.
Rod S Taylor et al.
Published Erratum
PharmacoEconomics - open. 2024 Jul;8(4):641. DOI:10.1007/s41669-024-00485-8 2024
Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs [0.03%]
肺癌患者中EORTC QLU-C10D测量属性的评估：LUX-LUNG四大中心临床试验的数据，应用六国评分表
Micha J Pilz,Simone Seyringer,Imad Al-Naesan et al.
Micha J Pilz et al.
Background: Cost-utility analysis generally requires valid preference-based measures (PBMs) to assess the utility of patient health. While generic PBMs are widely used, disease-specific PBMs may capture additional aspects...
Whither Decision-Analytic Modelling-Based Economic Evaluation for Health Care Decision Making? [0.03%]
基于决策分析模型的卫生技术经济评价的发展方向是什么？
Rachael Maree Hunter,Matthew Franklin
Rachael Maree Hunter
Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model [0.03%]
使用马尔可夫模型评估英国NHS糖尿病预防计划的长期成本效益
Emma McManus
Emma McManus
Background: In 2016, England launched the largest nationwide diabetes mellitus prevention programme, the NHS Diabetes Prevention Programme (NHS DPP). This paper seeks to evaluate the long-term cost-effectiveness of this p...
Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India's Chhattisgarh State? [0.03%]
印度恰蒂斯加尔州非传染性疾病护理成本：哪种医疗服务提供者最经济？
Samir Garg,Narayan Tripathi,Kirtti Kumar Bebarta
Samir Garg
Background: Non-communicable diseases (NCDs) affect a large number of people globally and their burden has been growing. Healthcare for NCDs often involves high out-of-pocket expenditure and rising costs of providing serv...
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances [0.03%]
艰难处境中的良好决策：英国NICE的路径图试点项目
Dawn Lee,Darren Burns,Ed Wilson
Dawn Lee
Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older [0.03%]
重组水痘带状疱疹疫苗在50岁及以上加拿大成人中的最新公共卫生影响及成本效益分析
Sydney George,Justin Carrico,Katherine A Hicks et al.
Sydney George et al.
Objectives: The aim of this study was to update previously estimated public health impact and cost effectiveness of recombinant zoster vaccine (RZV) for the prevention of herpes zoster (HZ) in Canadians aged ≥50 years us...
Behind the Scenes: A Qualitative Investigation of Interviewers' Performance in EQ-5D Valuation Studies [0.03%]
幕后调查：EQ-5D评估研究中访谈者表现的定性分析
Carlotta Varriale,Giovanni Andrulli,Michela Meregaglia et al.
Carlotta Varriale et al.
Background: The EuroQol Valuation Technology (EQ-VT) protocol is currently employed by the valuation studies of the EQ family of instruments worldwide. To date, all the evidence in support of the quality control (QC) orig...